EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Aprocitentan: A new development of resistant hypertension

Yao Yao iD, Bin Fan, Bin Yang, Zixuan Jia, Bao Li

The Journal of Clinical Hypertension · 2023

DOI: 10.1111/jch.14686 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Hypertension, 2023. Verfasst von Yao Yao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: Hypertension. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the blood pressure threshold for commencing antihypertensive treatment diminishes, the cohort suffering from resistant hypertension (RH) correspondingly expands. Notwithstanding the availability of known antihypertensive medications, there exists a conspicuous lacuna in therapeutic options specifically intended for the management of RH. Currently, aprocitentan is the sole endothelin receptor antagonist (ERA) under development for addressing this pressing clinical challenge. Aprocitentan (ACT‐132577), deriving its active form as a metabolite of macitentan, demonstrates oral potency as a dual endothelin (ET) receptor antagonist. This compound effectively obstructs the binding of endothelin‐1 (ET‐1) to both ETA and ETB receptors, exhibiting an inhibitory potency ratio of 1:16. Clinical investigation of aprocitentan has advanced to phase 3 trials, yielding promising preliminary outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionHumansAntihypertensive AgentsEndothelin Receptor AntagonistsBlood PressureEndothelin-1PyrimidinesSulfonamides

Stichwörter der Autor:innen

ACT-132577PRECISIONaprocitentanphase 3 clinical trialsresistant hypertension

Substanzen

Antihypertensive AgentsEndothelin Receptor AntagonistsEndothelin-1aprocitentanPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Department of Cardiology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
  • Shanxi Medical University, Taiyuan, Shanxi, China.

ORCID-Profile: Yao Yao

Zitieren

APA

Yao, Y., Fan, B., Yang, B., Jia, Z., & Li, B. (2023). Aprocitentan: A new development of resistant hypertension. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14686

Vancouver

Yao Y, Fan B, Yang B, Jia Z, Li B. Aprocitentan: A new development of resistant hypertension. The Journal of Clinical Hypertension. 2023. doi:10.1111/jch.14686

BibTeX
@article{Yao2023,
  author = {Yao, Yao and Fan, Bin and Yang, Bin and Jia, Zixuan and Li, Bao},
  title = {Aprocitentan: A new development of resistant hypertension},
  journal = {The Journal of Clinical Hypertension},
  year = {2023},
  doi = {10.1111/jch.14686}
}
Kostenlos starten →